These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32048753)

  • 1. Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients.
    Basilisco G;
    Aliment Pharmacol Ther; 2020 Mar; 51(6):629-636. PubMed ID: 32048753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li F; Fu T; Tong WD; Liu BH; Li CX; Gao Y; Wu JS; Wang XF; Zhang AP
    Mayo Clin Proc; 2016 Apr; 91(4):456-68. PubMed ID: 27046523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype.
    Solem CT; Patel H; Mehta S; Mody R; Macahilig C; Gao X
    Curr Med Res Opin; 2016 May; 32(5):899-905. PubMed ID: 26836030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation.
    Neri L; Iovino P;
    Neurogastroenterol Motil; 2016 Apr; 28(4):581-91. PubMed ID: 26867677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
    Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
    Jadallah KA; Kullab SM; Sanders DS
    World J Gastroenterol; 2014 Jul; 20(27):8898-909. PubMed ID: 25083062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
    Khoshoo V; Armstead C; Landry L
    Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
    Tack J
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partially hydrolyzed guar gum in the treatment of irritable bowel syndrome with constipation: effects of gender, age, and body mass index.
    Russo L; Andreozzi P; Zito FP; Vozzella L; Savino IG; Sarnelli G; Cuomo R
    Saudi J Gastroenterol; 2015; 21(2):104-10. PubMed ID: 25843197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
    Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for pelvic floor dyssynergia in patients with irritable bowel syndrome.
    Suttor VP; Prott GM; Hansen RD; Kellow JE; Malcolm A
    Dis Colon Rectum; 2010 Feb; 53(2):156-60. PubMed ID: 20087090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey.
    Rangan V; Ballou S; Shin A; Camilleri M; ; Lembo A
    Gastroenterology; 2020 Feb; 158(3):786-788.e1. PubMed ID: 31711922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents.
    Tse Y; Armstrong D; Andrews CN; Bitton A; Bressler B; Marshall J; Liu LW
    Can J Gastroenterol Hepatol; 2017; 2017():8612189. PubMed ID: 28271055
    [No Abstract]   [Full Text] [Related]  

  • 20. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
    Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
    Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.